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By hydrophobic gel permeation and high pressure liquid chromatography we isolated from pig intestinal 
mucosa a peptide which corresponds to proglucagon 78-107 as suggested by chromatography and determi- 
nation of its N-terminal sequence. Natural and synthetic proglucagon 78-107 dose dependently and potently 
increased insulin secretion from the isolated perfused pig pancreas. Proglucagon 78-107 also secreted by 
the small intestine may participate in the hormonal control of insulin secretion. 
Glucagon-like peptide; Incretin; Monobasic cleavage 
1. INTRODUCTION 
The mammalian glucagon precursor (pro- 
glucagon) is a 180 amino acid peptide. Besides 
glucagon itself it contains two glucagon-like se- 
quences, originally designated ‘glucagon-like pep- 
tides 1 and 2’ (GLP-1 and GLP-2), which are 
separated by a 13 amino acid spacer sequence 
[ 1,2]. The glucagon-like sequences (GLP-1 shown 
in fig.l), which are about 50% homologous with 
glucagon, are flanked by pairs of basic amino 
acids, putative processing sites. Proglucagon ap- 
pears to be processed ifferently in the mammalian 
pancreas and small intestine [3-51. In the pig and 
rat pancreas the following peptides are produced 
and secreted upon appropriate stimulation: (i) 
glucagon; (ii) glicentin-related pancreatic peptide 
(GRPP) corresponding to proglucagon l-30; (iii) a 
large peptide that contains both the GLP-1 and the 
GLP-2 sequences [4-61. In the pig small intestine 
the major secreted products are the 69 amino acid 
glucagon-containing peptide, glicentin, and the 
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two glucagon-like sequences GLP-1 and GLP-2 as 
separate peptides, not as parts of one large peptide 
[4]. Gel filtration studies have shown that the 
glucagon-like peptides secreted from the pig small 
intestine have approximately the same size as syn- 
thetic replicas of the two glucagon-like peptides 
synthesized according to their structure as 
predicted from the proglucagon sequence [4]. The 
exact structure of the ileal glucagon-like peptides is 
not known, however. We therefore isolated the 
naturally occurring glucagon-like peptide 1 from 
acid-ethanol extracts of pig small intestinal mucosa 
and determined part of its sequence. In addition, 
we studied biological effects of the peptide as well 
as the effects of a peptide synthesized according to 
the structure of the natural peptide. 
2. MATERIALS AND METHODS 
2.1. Isolation of proglucagon 78-107 
Ileal mucosa was excised from anaesthesized 
pigs and immediately frozen. Acid ethanol-extracts 
were prepared according to method II in [7]. In 
short, frozen tissue was homogenized in 4 vols acid 
ethanol and centrifuged. 5 vols cold diethyl ether 
were added to the supernatant and the aqueous 
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phase was isolated at - 50°C. The resulting 
precipitate was then dissolved in distilled water 
containing 8 mol/l urea. The GLP-1 immunoreac- 
tive peptide was isolated in 4 consecutive steps. 
The procedure was monitored with a radioim- 
munoassay developed for synthetic GLP-1 (pro- 
glucagon 71-107) [4], using antiserum 1953 raised 
against synthetic GLP-1, 1251-labeled synthetic 
GLP-1, and synthetic GLP-1 (l-37 amide, code 
no.7166, Peninsula, Belmont, CA, USA) for stan- 
dards. Determined with this radioimmunoassay ex- 
tracts of the pig ileum mucosa contain 88 + 
4 pmol/g of immunoreactive GLP-1. Extract of 
1 kg mucosa corresponding to ileal mucosa from 3 
pigs of 40-45 kg was applied to a 3 x 15 cm glass 
column packed with Techoprep C18, 40-63 pm 
(HPLC Technology, England), and eluted with a 
gradient of 20-80% ethanol in water containing in 
addition 0.01% trifluoroacetic acid (TFA, Pierce, 
Rockford, IL). From the GLP-1 immunoreactive 
fractions the ethanol was removed by evaporation 
and the pool was applied to a 50 x 1000 mm 
(K SO/lOO) column packed with SephadexR G-50, 
fine grade (Pharmacia, Uppsala, Sweden) and 
eluted with 0.5 M acetic acid at a flow rate of 
1 ml/min at 4°C. GLP-1 immunoreactive frac- 
tions were then subjected to reverse-phase high- 
pressure liquid chromatography on an 8 x 250 mm 
NucleosilR Cl8 column employing LKB pumps 
and detectors (LKB, Bromma, Sweden). The col- 
umn was eluted with water containing 0.1% TFA 
and a gradient of acetonitrile (grade S, Rathburn 
Chemicals, Ltd, Walkerburn, Scotland) from 0 to 
80%. Finally, GLP-1 immunoreactive fractions 
were subjected to isocratic HPLC with 43% 
ethanol in water containing in addition 0.01% 
TFA as the mobile phase. 
2.2. Sequence determination 
Solvent was removed under vacuum from the 
HPLC purified peptide. It was reconstituted in 
0.06 ml of 10% TFA in water and subjected to 
automated sequence analysis by sequential Edman 
degradation on an Applied Biosystems 470A gas- 
phase sequenator with the 02 NVAC program 
(batch 1) or the 02RPTH program (batch 2), pro- 
grammes modified from Hunkapillar et al. [S], 
available at Applied Biosystems, Foster City, CA, 
USA. All chemicals were purchased from Applied 
Biosystems. The phenylthiohydantoin derivatives 
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of amino acids were either (batch 1) characterized 
by HPLC on a Hewlett-Packard 1084 liquid 
chromatograph with a 0.45 x 25 cm column of CN 
(5 pm particles, IBM Instruments) and a sodium 
acetateiacetonitrile gradient elution system as 
described [9], or, in the case of batch 2, the 
samples from the sequenator were methylated 
before HPLC by treating the dried derivatives with 
acidified methanol (1 M HCl in methanol; Applied 
Biosystems) for 10 min at 50°C. The amino acid 
derivatives were then characterized on an Applied 
Biosystems PTH column, 2.1 x 22 cm, using the 
elution system recommended by the manufacturer. 
Aminobutyric acid was used as internal standard 
during the HPLC for correction of elution time 
and for quantifying the amino acid derivatives. 
2.3. Effect of natural and synthetic GLP-1 on 
insulin secretion 
Synthetic proglucagon 78-108 amide was ob- 
tained from Peninsula Laboratories (San Carlos, 
CA) by custom synthesis (lot no.008802; peptide 
purity by amino acid analysis 72%). Before the 
peptide was used in physiological studies, it was 
purified to homogeneity by isocratic HPLC as 
described above. Sequence determination of syn- 
thetic peptide confirmed the structure as being pro- 
glucagon 78-107 amide. The biological effect of 
both the synthetic proglucagon 78-107 fragment 
and the isolated natural peptide was studied using 
perfused porcine pancreas, prepared and perfused 
as described in [lo]. The pancreas was isolated 
together with the supplying arteries and veins and 
perfused with an artificial medium consisting of 
Krebs-Ringer bicarbonate buffer, containing 15% 
washed bovine erythrocytes, 0.1% human serum 
albumin (reins& trocken, Behringwerke Marburg, 
FRG), 5 or 7 mmol/l glucose, 5% dextran T-70, 
aprotinin 100000 KIU/l (TrasylolR, Bayer, 
Leverkusen, FRG), and 5 mmol/l of a mixture of 
amino acids (Amodex Asa, Pharmacia, Uppsala, 
Sweden). The medium was gassed with 95% ox- 
ygen and 5% COz. Synthetic proglucagon 78-107 
was infused intra-arterially for 5 or 10 min periods 
in doses corresponding to final perfusate concen- 
trations of 10-‘“-10-8 mol/l. Efflrrent fractions 
were collected every minute and kept on ice until 
centrifugation. The supernatants were stored at 
-20°C until assay. Insulin was measured in all 
fractions as described earlier [lo]. 
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3. RESULTS AND DISCUSSION 
The results of the isolation procedure are shown 
in fig.2. A homogeneous peak of immunoreactive 
GLP-1 was eluted from the Cl8 TechoprepR col- 
umn, and was further purified by gel filtration and 
repeated HPLC. The sequence of the first 17 
amino acids is shown in table 1. This sequence cor- 
responds to proglucagon 78-94; in other words, a 
truncated form of GLP-1. By gel filtration on 
Sephadex G 50 columns the natural peptide eluted 
exactly at the position of synthetic proglucagon 
78-107 amide. In addition, on analytical reverse- 
phase HPLC using a 24-48% acetonitrile gradient 
over 45 min the natural and the synthetic peptide 
had the same retention time (26 min). This strong- 
ly suggests that the natural peptide corresponds to 
proglucagon 78-107. In the present study we could 
not determine whether the natural peptide has a 
free cu-carboxyl group or is amidated. An amidated 
form was chosen for the synthetic peptide because 
Species 
Human 
Cx 
Hamster 
Rat 
Guinea pig 
Anglerfish 
Salmon 
Catfish 
Suecies 
Human 
ox 
Hamster 
Rat 
Guinea pig 
Anglerfish 
Salmon 
Catfish 
of the presence in proglucagon of a glycine residue 
after the C-terminal dibasic flanking sequences of 
GLP-1; in many propeptides this sequence gives 
rise to carboxyamidation during the posttransla- 
tional processing [111. 
According to our results, the cleavage of pro- 
glucagon to release GLP-1 does not occur at the 
expected site of the pair of basic amino acids (69 
and 70) but after the single basic amino acid at 
position 77. Similar monobasic proteolytic pro- 
cessing is found for many precursors as recently 
reviewed [12]. The natural porcine GLP-1, which 
according to the present study corresponds to pro- 
glucagon 78-107 amide, is thus very similar to 
anglerfish, catfish and salmon GLP-1 ([13-151; see 
fig.1). In fact, the six amino acids between the 
classical dibasic cleavage and the monobasic 
cleavage site are not encoded for by the anglerfish 
gene [ 131. After removal of the 6 N-terminal amino 
acids of GLP-1 the sequence homology of the re- 
maining peptide with glucagon is even more pro- 
Residue no. in human proglucagon 
Residue no. in human nroglucagon 
6 
eu Glu Gly Gln 1 Ala Lys Glu Ph Ile Ala Val Lys Gly Arg Gly Arg Arg 
I, 1, I, 0 I, I, I, I, 0 1, loo I, ,I @@ II II II II 11 107 11 11 I, 110 , 
II 11 II 11 II II 11 II 11 11 11 II (1 II II 11 11 II II II 
11 II I, II II II II 11 71 II I, It II 11 11 II I, I, I, I, 
II II II 11 I, 11 11 9, 1, 1, 11 ,, 11 1, 11 I, (1 I, 1, II 
" Lys Asp " " Ile " Asp 'I Val Asp Arg " Lys Ala 11 Gin Val " " 
II Gin 11 II 1, ,, v Asp t4 Val Ser w w Lys Ser U v Ala + + 
II Gin 11 II It 11 " Asn " II Thr I1 )t Lys Ser N Gln Pro Lys Pro 
Fig.1. Sequences from 8 species of proglucagon regions containing glucagon-like peptide 1. Glucagon-like peptide-l 
containing sequences of proglucagon from all species whose proglucagon structure has been determined 
[ 1,2,13-15,23,24]. The peptide which was originally designated GLP-1 (of hamster proglucagon) corresponds to 
proglucagon 72-108. Amino acids which occupy the same position in the glucagon molecule are encircled. Amino acids 
72-77 are not coded for in the anglerfish gene. (” ” ) Same amino acid as in human proglucagon; ( + + ) gene structure 
not known [14,15]; (- - ) amino acids not encoded for in anglerfish gene [13]. Circle around amino acids indicates 
amino acids in same positions as human glucagon. Vertical line between amino acids 77 and 78 indicates position of 
N-terminal amino acid in glucagon-like peptide 1 from pig, anglerfish, salmon and catfish. 
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Fig.2. Isolation of porcine natural GLP-1. The 
concentration of natural GLP-1 was monitored by 
radioimmunoassay. Upper left part shows the results of 
hydrophobic chromatography. Extract of 1 kg mucosa 
was applied to the column and eluted with a gradient of 
ethanol in water (right ordinate scale). Upper right part 
shows gel filtration of peak fractions from the first step. 
Lower left part shows reverse-phase HPLC of peak 
fractions from the gel filtration. The column was eluted 
with a gradient of acetonitrile in water (right ordinate 
scale). The lower right part shows the results of isocratic 
HPLC (43% ethanol in water). The dotted line shows 
UV-absorption at 280 nm. 
nounced (see fig.1). Since the N-terminal part of 
the glucagon molecule is essential for its biological 
activity [16], proglucagon 78-107 might be ex- 
pected to show glucagon-like effects. So far, only 
few studies on the biological effects of the 
glucagon-like peptides GLP-1 and GLP-2 have 
been reported. Ghiglione et al. [17] found no effect 
of synthetic GLP-1 (l-36 amide, Peninsula) on 
blood glucose or insulin levels in fasting rabbits in 
what was considered as pharmacological doses. 
Schmidt et al. [ 181 found a weak insulinotropic ef- 
fect of synthetic GLP-1 (l-36 amide, code 
no.7166, Peninsula), but not of synthetic GLP-2 
(l-34, code no.7156) on isolated rat islet at rather 
high concentrations of GLP-1 and GLP-2 and in 
the presence of 10 mmol/l glucose. We [19] recent- 
ly demonstrated inhibition of gastric acid secretion 
in healthy volunteers during submaximal pen- 
Table 1 
Amino acid Sequence Amino Yield of amino 
in mam- cycle acid acid phenyl- 
malian pro- thiohydantoin de- 
glucagon rivative (pmol) 
78-96 
Batch 1 Batch 2 
His 
Ala 
Glu 
Gly 
Thr 
Phe 
Ser 
Ser 
Asp 
Val 
Ser 
Ser 
Tyr 
Leu 
Glu 
Gly 
Gln 
Ala 
1 His 
2 Ala 
3 Glu 
4 Gly 
5 Thr 
6 Phe 
7 X 
8 Ser 
9 Asp 
10 Val 
11 X 
12 X 
13 T yr 
14 Leu 
15 Glu 
16 X 
17 Gin 
18 X 
37 - 
108 18 
76 105 
81 54 
43 _ 
80 64 
_ _ 
22 - 
_a 32 
64 47 
_ _ 
_ - 
46 24 
_ 14 
16 
_ 
16 
- 
a The unmethylated PTA-Asp could be identified close 
to the injection artifact but was not quantified 
Sequence determination of the GLP-1 immunoreactive 
peptide isolated from porcine intestinal mucosa. The 
results of Edman degradation of two independent 
batches of peptide are shown. Identification and 
quantitation of the phenylthiohydantoin derivatives 
were performed on a Hewlett-Packard 1084 (1) or 1090A 
(2) chromatograph. The amino acid derivatives were 
methylated before identification in batch 2. (-) 
Uncertain identification 
tagastrin stimulation when GLP-1 (l-36 amide) 
was infused at a rate of 400 ng/kg x h. This infu- 
sion rate increased the plasma levels of im- 
munoreactive GLP-1 from 90 to about 
600 pmol/l. We found no effect of synthetic 
GLP-1 (code 7166) or GLP-2 (code 7156; both 
from Peninsula) on the isolated perfused pancreas 
in concentrations up to lo- M either on the ex- 
ocrine or the endocrine secretion [4]. By contrast, 
natural GLP-1, isolated from pig intestinal mucosa 
strongly increased insulin secretion from the same 
preparations. At a concentration of lo-” mol/l of 
natural GLP-1 (determined by radioimmunoassay) 
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and 7 mmol/l glucose in the perfusate insulin 
secretion increased from 21.9 f 2.6 (average f SE 
of 5 min basal secretion in 2 preparations) to 
3 1.6 + 1.1 pmol/min (average of 5 min stimulated 
secretion); and at low9 mol/l insulin secretion in- 
creased from 32.0 + 1.1 to 73.6 + 2.9 pmol/min. 
A similar increase in insulin secretion was observed 
after administration of synthetic proglucagon 
78-107 amide (figs 3,4). After arterial infusion of 
synthetic proglucagon 78-107 at lo-” mol/l in- 
sulin secretion approximately doubled and increas- 
ed more than 4-fold after lob9 mol/l. Thus this 
peptide is at least as potent and effective as gastric 
inhibitory polypeptide (GIP), hitherto the most 
pmolll 10-10 hi 5x10-'Ok4 
I I I I 
potent intestinal insulinotropic hormone [20]. At 
5.0 mmol/l glucose in the perfusate the in- 
sulinotropic effect was less conspicuous; but the 
relative increase in insulin secretion was approx- 
imately the same (not shown). 
On this background it might be suggested that 
the reported effects of GLP-1 in high doses could 
be due to enzymatic conversion of GLP-1 to pro- 
glucagon 78-107 in the medium. Trypsin-like en- 
zymatic activity, which may be difficult to avoid in 
pancreatic tissue incubation studies, might be 
responsible for such conversion, due to the 
presence of a basic amino acid residue at position 
76. 
Proglucagon 76 -107 
e 
minutes 
Fig.3. Insulin secretion of the isolated perfused pig pancreas in response to infusion of synthetic proglucagon 78-107 
amide. The ordinate shows the concentration of insulin in the effluent. The final perfusate concentrations of 
proglucagon 78-107 amide are indicated in boxes. Results of a single representative xperiment. Perfusate glucose 
concentration was 7.0 mmol/l. 
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PrnOl/MiN 
200 
r 
100 t 
I t+++t 0 
1 5 10 1 5 10 Nl”“bS 
Fig.4. Insulin secretion (pmol/min) of the isolated 
perfused pig pancreas in response to infusion of 
synthetic proglucagon 78-107 amide at lo-” and 
10m9 mol/l. Glucose concentration in perfusate was 
7 mmol/l. Mean it SE. n = 4. 
Previously, we found that the concentration of 
immunoreactive GLP-1 in plasma rose in response 
to a mixed meal in human volunteers [21]. 
Lauritsen et al. [22] have shown that the lower in- 
testine contributes significantly to the in- 
sulinotropic effect of luminal versus intravenous 
glucose administration (the incretin effect). Our 
results suggest that proglucagon 78-107 may be 
the incretin of the lower gut. 
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